

Saskia A C Luelmo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6844537/publications.pdf>

Version: 2024-02-01

18
papers

1,121
citations

1162889

8
h-index

839398

18
g-index

18
all docs

18
docs citations

18
times ranked

1508
citing authors

#	ARTICLE	IF	CITATIONS
1	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	1.3	27
2	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	0.8	274
3	The prognostic value of the 12€, 6€, 3€-and 1€-month "Surprise Question"™ in cancer patients: A prospective cohort study in three hospitals. <i>European Journal of Cancer Care</i> , 2022, 31, e13551.	0.7	4
4	Pancreatic Cancer Surveillance in Carriers of a Germline <i>CDKN2A</i> Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. <i>Journal of Clinical Oncology</i> , 2022, 40, 3267-3277.	0.8	35
5	Identifying the Need to Discuss Infertility Concerns Affecting Testicular Cancer Patients: An Evaluation (INDICATE Study). <i>Cancers</i> , 2021, 13, 553.	1.7	6
6	The self-perceived palliative care barriers and educational needs of clinicians working in hospital primary care teams and referral patterns: lessons learned from a single-center survey and cohort study. <i>Annals of Palliative Medicine</i> , 2021, 10, 2620-2637.	0.5	4
7	Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3574-3574.	0.8	3
8	Circulating <i>TP53</i> mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110337.	1.4	8
9	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10902.	1.8	9
10	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. <i>Cancers</i> , 2021, 13, 6088.	1.7	8
11	Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies. <i>Oncologist</i> , 2020, 25, e341-e350.	1.9	5
12	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1763-1773.	0.8	665
13	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	2.3	26
14	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. <i>Journal of Clinical Oncology</i> , 2019, 37, 4564-4564.	0.8	2
15	Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 246-252.	1.0	9
16	Risk of multiple pancreatic cancers in <i>CDKN2A</i> -p16-Leiden mutation carriers. <i>European Journal of Human Genetics</i> , 2018, 26, 1227-1229.	1.4	9
17	Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. <i>Journal of Clinical Pathology</i> , 2017, 70, 174-178.	1.0	24
18	Food intervention to make therapy with pazopanib more patient-friendly and affordable.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11040-11040.	0.8	3